SAN DIEGO, Jan. 11, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the online publication of a new article1 in The Lancet Infectious Diseases detailing results from the company's completed Phase 2 proof-of-concept trial of its TransVax™ therapeutic vaccine, which is designed to control cytomegalovirus (CMV) infection or reactivation in transplant recipients. Separately, the company is participating this week in a two-day public workshop jointly sponsored by multiple agencies within the U.S. Department of Health and Human Services (HHS), "The Development and Evaluation of Human Cytomegalovirus Vaccines," in connection with the company's CyMVectin™ prophylactic vaccine, which is designed to elicit protective immunity in young women before they become pregnant, thereby protecting the fetus from transmission of CMV during pregnancy.
